Scott T. Rottinghaus, M.D.

Scott T. Rottinghaus, M.D.

Chief Medical OfficeratEnanta Pharmaceuticals· In proxies 2022–2025

Pay in FY2025+7% from the year before · Enanta Pharmaceuticals stock +15.5% the same year

Scott T. Rottinghaus, M.D. was paid $1.3M in FY2025 (Sep), up 7%. Enanta Pharmaceuticals stock rose 15.5% that year.

Pay$100 in the stock at the end of FY21 → $21
Pay is from the Summary Compensation Table of each Enanta Pharmaceuticals proxy. The stock line is the value of $100 put in the stock at the start, from the price change of each fiscal year. Dividends are not in it.

Experience

  1. Enanta PharmaceuticalsPublic company · 4 yr
    • Chief Medical Officer2022 – Present · 4 yrStock in role -79%

Roles come from the proxy statements of each company.

Activity

For the press:Download CSVDownload PNGHow to use our data

Two people shown as one, or a wrong number?